Retatrutide (LY3437943) is a synthetic triple agonist of GLP-1, GIP, and glucagon receptors developed by Eli Lilly, enabling simultaneous modulation of appetite, glycemic control, energy expenditure, and lipid metabolism
Treating addiction Since Ozempic and Mounjaro have been become more common, patients have been reporting several unexpected side effects, such as a diminished desire to smoke or drink
Various plant receptors respond to stress stimuli thereby activating signalling pathways which involve secondary messengers, phytohormones, signal transducers and transcription factors (Gilroy et al
Nanomedicine-mediated ferroptosis targeting strategies for synergistic cancer therapy
Glutathione S-transferase mu in human lymphocyte and liver: role in modulating formation of carcinogen-derived DNA adducts
Micronutrient Risk on GLP-1 Medications GLP1 receptor agonists like semaglutide and dual GIP/GLP1 drugs like tirzepatide slow stomach emptying and reduce appetite
